

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8675 - CVC / TEVA'S WOMEN'S HEALTH BUSINESS

SECTION 1.2

Description of the concentration

On 16 November 2017, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) 139/2004 involving the acquisition of sole control of Teva's International Women's Health Business ("**Target Business**") by CVC Capital Partners SICAV-FIS S.A. (together with its subsidiaries and affiliates, the "**CVC Group**") within the meaning of Article 3(1)(b) of Council Regulation (EC) No 139/2004.

The primary business activities of the undertakings concerned are:

- (a) For CVC, the CVC Group manages and provides advice to investment funds and platforms;
- (b) For Target Business, the production and supply of women's health pharmaceutical products.